Last reviewed · How we verify
Danuglipron (danuglipron)
Danuglipron is a small-molecule GLP-1 receptor agonist.
Danuglipron, developed by Pfizer, currently holds a niche market position as a small-molecule GLP-1 receptor agonist with one approved indication. Its competitive advantage lies in its mechanism of action, which may offer an alternative to injectable GLP-1 receptor agonists like Liraglutide and Semaglutide. A key risk is the lack of clinical trial data, which could hinder its broader adoption and regulatory approvals. The pipeline outlook remains uncertain due to the requirement of a PD-L1 companion diagnostic for several potential indications, which may delay development and market entry.
At a glance
| Generic name | danuglipron |
|---|---|
| Sponsor | Pfizer |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Danuglipron works by activating the GLP-1 receptor, which plays a crucial role in glucose metabolism. This activation leads to improved diabetic control and weight reduction. The GLP-1 receptor agonist mechanism is distinct from other diabetes treatments, offering a novel approach to managing the condition.
Approved indications
- Treatment of acute and chronic pain
Common side effects
- Headache
- Nausea
- Diarrhoea
- Vomiting
- Fatigue
- Dizziness
- Constipation
- Hyperglycaemia
- Dyspepsia
- SARS-CoV-2 test positive
- Upper respiratory tract infection
- Abdominal pain
Drug interactions
- Warfarin
- Aspirin
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Alteplase
- Reteplase
- Tenecteplase
- Urokinase
- Streptokinase
- Abciximab
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Danuglipron CI brief — competitive landscape report
- Danuglipron updates RSS · CI watch RSS
- Pfizer portfolio CI